Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: An update for clinicians

Therapeutic Advances in Chronic Disease

Volumn 3, Issue 5, 2012, Pages 211-218

  Irving, Gordon ^a  

^a Swedish Pain and Headache Center   (United States)

Author keywords

Efficacy; Gabapentin; Once daily; Pharmacokinetics; Postherpetic neuralgia; Tolerability

Indexed keywords

ANTACID AGENT; GABAPENTIN; HYDROCODONE; MORPHINE; PLACEBO;

ARM PAIN; BACKACHE; CONSTIPATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVENING DOSAGE; FETOTOXICITY; FOOD; FOOD DRUG INTERACTION; HUMAN; LEG PAIN; LETHARGY; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 84868635151     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312452905     Document Type: Review

References (33)

1. Belgrade M. (1999) Following the clues to neuropathic pain. distribution and other leads reveal the cause and the treatment approach. Postgrad Med 106: 127–132, 135–140.
2. Berner B. Cowles V. (2006) Case studies in swelling polymeric gastric retentive tablets. Expert Opin Drug Deliv 3: 541–548.
3. Centers for Disease Control (CDC) (2011) Shingles (herpes zoster) clinical overview. www.cdc.gov/shingles/hcp/clinical-overview.html (accessed 10 October 2011).
4. Chen C. Cowles V. Hou E. (2011) Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol 51: 346–358.
5. Claxton A. Cramer J. Pierce C. (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23: 1296–1310.
6. Cundy K. Sastry S. Luo W. Zou J. Moors T. Canafax D. (2008) Clinical pharmacokinetics of Xp13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 48: 1378–1388.
7. Cunningham A. Dworkin R. (2000) The management of post-herpetic neuralgia. BMJ 321: 778–779.
8. Dimatteo M. Giordani P. Lepper H. Croghan T. (2002) Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 40: 794–811.
9. Dworkin R. Portenoy R. (1996) Pain and its persistence in herpes zoster. Pain 67: 241–251.
10. Eckhardt K. Ammon S. Hofmann U. Riebe A. Gugeler N. Mikus G. (2000) Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 91: 185–191.
11. Eisen S. Miller D. Woodward R. Spitznagel E. Przybeck T. (1990) The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150: 1881–1884.
12. Elwes R. Binnie C. (1996) Clinical pharmacokinetics of newer antiepileptic drugs. lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet 30: 403–415.
13. Gordi T. Hou E. Kasichayanula S. Berner B. (2008) Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 30: 909–916.
14. Gralise (2011) Package insert. Menlo Park, CA: Depomed, Inc.
15. Hou S. Cowles V. Berner B. (2003) Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst 20: 459–497.
16. Irving G. Jensen M. Cramer M. Wu J. Chiang Y. Tark M. et al. (2009) Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 25: 185–192.
17. Johnson R. Wasner G. Saddier P. Baron R. (2007) Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 7: 1581–1595.
18. Kaufman D. Kelly J. Rosenberg L. Anderson T. Mitchell A. (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287: 337–344.
19. Kriel R. Birnbaum A. Cloyd J. Ricker B. Jones Saete C. Caruso K. (1997) Failure of absorption of gabapentin after rectal administration. Epilepsia 38: 1242–1244.
20. Mao J. Chen L. (2000) Gabapentin in pain management. Anesth Analg 91: 680–687.
21. Mclean M. (1995) Gabapentin. Epilepsia 36(Suppl. 2): S73–S86.
22. Neurontin (2010) Package insert. New York: Pfizer Inc.
23. Odrcich M. Bailey J. Cahill C. Gilron I. (2006) Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain 120: 207–212.
24. Oxman M. Levin M. Johnson G. Schmader K. Straus S. Gelb L. et al. (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352: 2271–2284.
25. Rice A. Maton S. (2001) Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 94: 215–224.
26. Rowbotham M. Harden N. Stacey B. Bernstein P. Magnus-Miller L. (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280: 1837–1842.
27. Sang C. Sathyanarayana R. Carter F. Sweeney M. (2010) Gabapentin extended release for the once-daily treatment of post herpetic neuralgia. American Academy of Pain Management 21st Annual Meeting, Las Vegas, NV, USA.
28. Schmader K. (2002) Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 18: 350–354.
29. Stewart B. Kugler A. Thompson P. Bockbrader H. (1993) A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10: 276–281.
30. Striano P. Striano S. (2008) Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today (Barc) 44: 353–368.
31. Vollmer K. von Hodenberg A. Kolle E. (1986) Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 36: 830–839.
32. Wallace M. Irving G. Cowles V. (2010) Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig 30: 765–776.
33. Waterman K. (2007) A critical review of gastric retentive controlled drug delivery. Pharm Dev Technol 12: 1–10.